Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. We are also developing proprietary Lm-based antigen delivery products for patients suffering from more common cancers. Our lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors; ADXS-504, a Lm-based therapy for early-stage prostate cancer, and the intravenous gamma secretase inhibitor, AL101, for adenoid cystic carcinoma. AL102 (RINGSIDE) has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for...

Precision oncology,targeted therapy,drug development,companion diagnostics,biomarkers,oncology,and rare diseases

Ayala pharmaceuticals operates in the Pharmaceutical manufacturing industry.

Ayala pharmaceuticals's HQ phone number is +241 0202003

Ayala pharmaceuticals's revenue is < 1m

Ayala pharmaceuticals has 11 - 50 employees.